Showing 5771-5780 of 6961 results for "".
- Dermavant Sciences Appoints Dr. Philip M. Brown as Chief Medical Officerhttps://practicaldermatology.com/news/dermavant-sciences-appoints-dr-philip-m-brown-as-chief-medical-officer/2459949/Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, appointed Philip M. Brown, MD, JD, as Chief Medical Officer. With more than 25 years of experience leading clinical development programs, Dr. Brown most recently served as head of global pharmaceutical drug development at G
- Dr. Sandra Marchese Johnson, Yoseph Dalia Win Practical Dermatology®'s Best Paper of 2018 Awardhttps://practicaldermatology.com/news/dr-sandra-marchese-johnson-yoseph-dalia-win-practical-dermatologys-best-paper-of-2018-award/2459950/Fort Smith, Arkansas-based dermatologist Sandra Marchese Johnson MD, FAAD and Yoseph Dalia, BS took home Practical Dermatology®’s Best Paper of 2018 award for a Resident Resource Center submission that detailed the first reported case of facial rash following dupilumab
- Modernizing Medicine Introduces New Patient Engagement Toolshttps://practicaldermatology.com/news/modernizing-medicine-introduces-new-patient-engagement-tools/2459951/Modernizing Medicine has launched enhanced patient engagement tools powered by Relatient that are designed to reduce no-shows and improve patient compliance, satisfaction, and operational efficiency. Patients who do not show for appointments can be a significant cost and ef
- Glenmark Pharmaceuticals Enters US Branded Dermatology Segmenthttps://practicaldermatology.com/news/glenmark-pharmaceuticals-enters-us-branded-dermatology-segment/2457537/Glenmark Pharmaceuticals is entering into the branded dermatology segment in the United States. The branded portfolio for the US market will be developed and commercialized by Glenmark Therapeutics Inc., USA, a wholly owned subsidiary of Glenmark Holding, SA. This represents an imp
- National Rosacea Society: New Grants Available in 2019https://practicaldermatology.com/news/national-rosacea-society-new-grants-available-in-2019/2457536/The National Rosacea Society (NRS) has new grants available in 2019 to support research into potential causes and other key aspects of rosacea that may lead to improvements in its management, prevention, or potential cure. The deadline for submitting proposals for research grants in 2019 is
- RealSelf Forms Strategic Medical Advisory Councilhttps://practicaldermatology.com/news/realself-forms-strategic-medical-advisory-council/2457540/RealSelf, Inc. has formed a Strategic Medical Advisory Council with three operating boards. The RealSelf Strategic Advisory Council is made up of the Business Advisory Board, the Medical Review Advisory Board and the Industry Advisory Board, all of which are comprised of board-certified doctors a
- Almirall and X-Chem Team Up to Develop Oral Compounds for Dermatological Diseaseshttps://practicaldermatology.com/news/almirall-and-x-chem-team-up-to-develop-oral-compounds-for-dermatological-diseases/2457545/Almirall, S.A. signed a collaborative research and license agreement with the X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases, a strategic area for Almirall. X-Chem, Inc. is a privately held biotechnology company focused on applying its indus
- AD, Suicidal Thoughts and Attempts Linkedhttps://practicaldermatology.com/news/ad-suicidal-thoughts-and-attempts-linked/2457543/Patients with eczema may be more likely to have suicidal thoughts and attempts compared to their counterparts without eczema, according to a new study in JAMA Dermatology. Res
- Dermatologists Need More Info About Cannabinoidshttps://practicaldermatology.com/news/dermatologists-need-more-info-about-cannabinoids/2457549/Dermatologists are interested in learning more about cannabinoids and recommending them to patients, according to a new survey in Journal of Drugs in Dermatology. However, many are concerned about th
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track